EE05581B1 - Aripiprasooli ravimlahus peroraalseks manustamiseks - Google Patents

Aripiprasooli ravimlahus peroraalseks manustamiseks

Info

Publication number
EE05581B1
EE05581B1 EEP200300523A EEP200300523A EE05581B1 EE 05581 B1 EE05581 B1 EE 05581B1 EE P200300523 A EEP200300523 A EE P200300523A EE P200300523 A EEP200300523 A EE P200300523A EE 05581 B1 EE05581 B1 EE 05581B1
Authority
EE
Estonia
Prior art keywords
oral
aripiprazole
solution
oral administration
administration
Prior art date
Application number
EEP200300523A
Other languages
English (en)
Inventor
Parab Prakash
Chou Joyce
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23099862&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE05581(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of EE200300523A publication Critical patent/EE200300523A/et
Publication of EE05581B1 publication Critical patent/EE05581B1/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EEP200300523A 2001-04-25 2002-04-24 Aripiprasooli ravimlahus peroraalseks manustamiseks EE05581B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28671801P 2001-04-25 2001-04-25
PCT/US2002/013048 WO2002085366A1 (en) 2001-04-25 2002-04-24 Aripiprazole oral solution

Publications (2)

Publication Number Publication Date
EE200300523A EE200300523A (et) 2004-02-16
EE05581B1 true EE05581B1 (et) 2012-10-15

Family

ID=23099862

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300523A EE05581B1 (et) 2001-04-25 2002-04-24 Aripiprasooli ravimlahus peroraalseks manustamiseks

Country Status (37)

Country Link
US (1) US6977257B2 (et)
EP (2) EP2436384B2 (et)
JP (1) JP4401077B2 (et)
KR (1) KR100909329B1 (et)
CN (1) CN1512884B (et)
AR (1) AR033168A1 (et)
AT (1) ATE537831T1 (et)
AU (1) AU2002254722B2 (et)
BG (1) BG66177B1 (et)
BR (1) BR0208986A (et)
CA (1) CA2445276C (et)
CY (1) CY1112606T1 (et)
CZ (1) CZ306181B6 (et)
DK (1) DK1381367T3 (et)
EE (1) EE05581B1 (et)
ES (1) ES2377855T3 (et)
GE (1) GEP20053602B (et)
HK (2) HK1058316A1 (et)
HR (1) HRP20030870B1 (et)
HU (1) HU230456B1 (et)
IL (2) IL158202A0 (et)
IS (1) IS2863B (et)
MX (1) MXPA03009728A (et)
MY (1) MY129350A (et)
NO (1) NO324606B1 (et)
NZ (1) NZ528550A (et)
PE (1) PE20021086A1 (et)
PL (1) PL206882B1 (et)
PT (1) PT1381367E (et)
RS (1) RS52082B (et)
RU (1) RU2295960C2 (et)
SK (1) SK287948B6 (et)
TW (1) TWI337865B (et)
UA (1) UA76144C2 (et)
UY (1) UY27273A1 (et)
WO (1) WO2002085366A1 (et)
ZA (1) ZA200307797B (et)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770478B2 (en) * 2000-02-10 2004-08-03 The Regents Of The University Of California Erythrocytic cells and method for preserving cells
DE60327225D1 (de) * 2002-08-20 2009-05-28 Bristol Myers Squibb Co Aripiprazol-komplex-formulierung und verfahren
CN1867359B (zh) * 2003-10-08 2010-12-15 马林克罗特公司 哌甲酯溶液及其制药用途和制备方法
JP4836797B2 (ja) * 2003-10-23 2011-12-14 大塚製薬株式会社 放出制御性無菌注射アリピプラゾール製剤および方法
CA2552988A1 (en) * 2004-01-21 2005-08-04 Janssen Pharmaceutica Nv Mitratapide oral solution
JP2009508859A (ja) 2005-09-15 2009-03-05 エラン ファーマ インターナショナル リミテッド ナノ粒子アリピプラゾール製剤
US8865722B2 (en) * 2006-01-05 2014-10-21 Teva Pharmaceutical Industries Ltd. Wet formulations of aripiprazole
CN101351193A (zh) * 2006-01-05 2009-01-21 特瓦制药工业有限公司 阿立哌唑的干法制剂
JP4892264B2 (ja) * 2006-03-30 2012-03-07 高田製薬株式会社 リスペリドン水性液剤
ATE523602T1 (de) 2006-06-12 2011-09-15 Hadasit Med Res Service Mit durch antipsychotika induzierten extrapyramidalen symptomen assoziierte rgs2- genotypen
GB0618879D0 (en) 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
DK2170279T3 (en) * 2007-07-31 2018-03-12 Otsuka Pharma Co Ltd PROCEDURES FOR PREPARING AN ARIPIPRAZOL SUSPENSION AND A FREEZER DRIED FORMULATION
WO2009042166A1 (en) * 2007-09-25 2009-04-02 Panacos Pharmaceuticals, Inc. Liquid bevirimat dosage forms for oral administration
GB2456183A (en) * 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
EP2376088B1 (en) 2008-12-23 2017-02-22 Gilead Pharmasset LLC 6-O-Substituted-2-amino-purine nucleoside phosphoramidates
EA019295B1 (ru) 2008-12-23 2014-02-28 Джилид Фармассет, Ллс. Соединения пуриновых нуклеозидов и способ их получения
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
WO2010146872A1 (ja) * 2009-06-19 2010-12-23 株式会社メドレックス アリピプラゾールと有機酸を有効成分とする外用剤組成物
TR201000948A1 (tr) 2010-02-09 2011-08-22 Sanovel İlaç San.Ve Ti̇c.A.Ş. Aripiprazol formülasyonları.
JP2013527145A (ja) 2010-03-31 2013-06-27 ギリード・ファーマセット・エルエルシー リン含有活性化剤の立体選択的合成
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
EP2609923B1 (en) 2010-03-31 2017-05-24 Gilead Pharmasset LLC Process for the crystallisation of (s)-isopropyl 2-(((s)-(perfluorophenoxy)(phenoxy)phosphoryl)amino)propanoate
AR084044A1 (es) 2010-11-30 2013-04-17 Pharmasset Inc Compuestos 2’-espiro-nucleosidos
HUE065359T2 (hu) 2011-03-18 2024-05-28 Alkermes Pharma Ireland Ltd Szorbitán-észtereket tartalmazó gyógyászati készítmények
JO3410B1 (ar) * 2011-06-07 2019-10-20 Otsuka Pharma Co Ltd تركيبة أريبيبرازول مجفف بالتبريد
CN102846616B (zh) * 2011-06-27 2015-05-06 上海中西制药有限公司 一种阿立哌唑制剂及其制备方法
US9241876B2 (en) 2011-06-27 2016-01-26 Shanghai Zhongxi Pharmaceutical Corporation Aripiprazole medicament formulation and preparation method therefor
TWI632921B (zh) * 2011-10-19 2018-08-21 大塚製藥股份有限公司 口服溶液
CA2867121C (en) 2012-03-19 2021-05-25 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
WO2013142205A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
CA2867123C (en) 2012-03-19 2021-02-16 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising water-insoluble antipsychotic agents and glycerol esters
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
US20150174247A1 (en) * 2012-06-29 2015-06-25 Maruishi Pharmaceutical Co., Ltd. Oral pharmaceutical preparation of aripiprazole
JP5341282B1 (ja) * 2012-06-29 2013-11-13 丸石製薬株式会社 アリピプラゾールの経口医薬製剤
KR101571670B1 (ko) 2012-08-08 2015-11-25 주식회사 씨엠지제약 아리피프라졸을 포함하는 경구용 속용 필름 제제
US9193685B2 (en) 2012-09-19 2015-11-24 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
US9452134B2 (en) * 2012-09-26 2016-09-27 Bristol-Myers Squibb Company Apixaban solution formulations
US8568747B1 (en) 2012-10-05 2013-10-29 Silvergate Pharmaceuticals, Inc. Enalapril compositions
US20140107130A1 (en) * 2012-10-11 2014-04-17 Antrim Pharmaceuticals, LLC Oral Solution Formulations of Aripiprazole
PL2908859T3 (pl) * 2012-10-16 2017-10-31 Arven Ilac Sanayi Ve Ticaret As Formulacje arypiprazolu
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
JP6203682B2 (ja) * 2013-07-10 2017-09-27 共和薬品工業株式会社 アリピプラゾール含有水性液剤
CN103393594A (zh) * 2013-08-22 2013-11-20 万特制药(海南)有限公司 一种新的阿立哌唑的制剂组合物
CN110368360A (zh) 2014-03-20 2019-10-25 奥克梅斯制药爱尔兰有限公司 具有增加的注射速度的阿立哌唑制剂
WO2016189504A1 (en) * 2015-05-28 2016-12-01 Leiutis Pharmaceuticals Pvt Ltd Non-lyophilized compositions of aripiprazole and methods of preparation thereof
JP6039849B1 (ja) * 2015-06-12 2016-12-07 高田製薬株式会社 アリピプラゾール含有内用液剤
WO2017025930A1 (en) * 2015-08-12 2017-02-16 Ftf Pharma Private Limited Oral solution of aripiprazole
US9463183B1 (en) 2015-10-30 2016-10-11 Silvergate Pharmaceuticals, Inc. Lisinopril formulations
US9669008B1 (en) 2016-03-18 2017-06-06 Silvergate Pharmaceuticals, Inc. Enalapril formulations
CN108434146A (zh) * 2017-02-16 2018-08-24 天津国际生物医药联合研究院 一种hiv-1整合酶抑制剂的溶液剂及其制备方法和应用
CN109498556A (zh) * 2017-09-15 2019-03-22 万特制药(海南)有限公司 阿立哌唑口服溶液及其制备方法
CN112423754A (zh) 2018-03-05 2021-02-26 奥克梅斯制药爱尔兰有限公司 阿立哌唑的给药策略
CN112666267B (zh) * 2019-10-15 2023-09-26 上海上药中西制药有限公司 一种阿立哌唑药品有关物质的检测方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU843739A3 (ru) 1978-02-17 1981-06-30 Карл Томэ Гмбх (Фирма) Способ получени карбостириловыхили ОКСиНдОлОВыХ пРОизВОдНыХ
JPS54130587A (en) 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
PH17194A (en) * 1980-03-06 1984-06-19 Otsuka Pharma Co Ltd Novel carbostyril derivatives,and pharmaceutical composition containing the same
JPS5959663A (ja) 1982-09-29 1984-04-05 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体−シクロデキストリン包接化合物
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JP3265680B2 (ja) * 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
US5457099A (en) 1992-07-02 1995-10-10 Sawai Pharmaceutical Co., Ltd. Carbostyril derivatives and antiallergic agent
TW254855B (et) * 1993-07-28 1995-08-21 Otsuka Pharma Co Ltd
WO1998043673A1 (en) * 1997-03-31 1998-10-08 Johnson & Johnson Consumer Companies, Inc. Solvent system for enhanced penetration of pharmaceutical compounds
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
JP2002524397A (ja) * 1998-09-03 2002-08-06 アルサイド コーポレーション 耐凍結性の局所用殺菌剤及びそれに関連する方法
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
US20020076437A1 (en) * 2000-04-12 2002-06-20 Sanjeev Kothari Flashmelt oral dosage formulation

Also Published As

Publication number Publication date
UA76144C2 (uk) 2006-07-17
HU230456B1 (hu) 2016-07-28
HRP20030870B1 (en) 2011-10-31
KR100909329B1 (ko) 2009-07-24
DK1381367T3 (da) 2012-04-10
AR033168A1 (es) 2003-12-03
US20020193438A1 (en) 2002-12-19
RS52082B (sr) 2012-06-30
HRP20030870A2 (en) 2004-06-30
CA2445276C (en) 2009-10-13
EP2436384A2 (en) 2012-04-04
EE200300523A (et) 2004-02-16
UY27273A1 (es) 2002-11-29
HUP0303946A3 (en) 2005-06-28
EP2436384A3 (en) 2012-09-19
BR0208986A (pt) 2004-04-20
ATE537831T1 (de) 2012-01-15
BG108216A (bg) 2004-12-30
BG66177B1 (bg) 2011-11-30
HK1058316A1 (en) 2004-05-14
PE20021086A1 (es) 2002-12-14
CY1112606T1 (el) 2016-02-10
RU2003132426A (ru) 2005-04-20
CZ306181B6 (cs) 2016-09-14
GEP20053602B (en) 2005-08-10
IS2863B (is) 2013-12-15
NO20034705D0 (no) 2003-10-21
MY129350A (en) 2007-03-30
CN1512884A (zh) 2004-07-14
ES2377855T3 (es) 2012-04-02
NO20034705L (no) 2003-11-28
IS6994A (is) 2003-10-14
TWI337865B (en) 2011-03-01
WO2002085366A1 (en) 2002-10-31
JP2004532225A (ja) 2004-10-21
CZ20032821A3 (cs) 2004-09-15
CN1512884B (zh) 2010-05-26
IL158202A (en) 2008-04-13
PL364666A1 (en) 2004-12-13
HK1168792A1 (en) 2013-01-11
HUP0303946A2 (hu) 2004-04-28
ZA200307797B (en) 2004-10-06
EP1381367B1 (en) 2011-12-21
SK287948B6 (sk) 2012-06-04
CA2445276A1 (en) 2002-10-31
EP1381367A1 (en) 2004-01-21
PT1381367E (pt) 2012-03-01
YU84703A (sh) 2006-08-17
JP4401077B2 (ja) 2010-01-20
EP2436384B2 (en) 2018-05-23
AU2002254722B2 (en) 2006-11-09
IL158202A0 (en) 2004-05-12
SK12642003A3 (sk) 2004-07-07
EP1381367A4 (en) 2009-07-01
KR20030096332A (ko) 2003-12-24
EP2436384B1 (en) 2015-06-10
RU2295960C2 (ru) 2007-03-27
NZ528550A (en) 2005-03-24
MXPA03009728A (es) 2004-01-29
NO324606B1 (no) 2007-11-26
PL206882B1 (pl) 2010-10-29
US6977257B2 (en) 2005-12-20

Similar Documents

Publication Publication Date Title
EE05581B1 (et) Aripiprasooli ravimlahus peroraalseks manustamiseks
NO20033556L (no) Farmasöytiske formuleringer
NO20033384D0 (no) Farmasöytisk formulering
NO20033815D0 (no) Farmasöytiske salter
EE200300416A (et) Ravimvorm
NO20040125L (no) Enterale formuleringer
ATE285752T1 (de) Inhalationskapseln
NO20035627D0 (no) Farmasöytisk formulering
NO20035315D0 (no) Farmasöytiske kombinasjoner
DE50209245D1 (de) Neuroprotektives medikament
NO20034556L (no) Imidazotriazinon-holdige sammensetninger for nasal administrering
DE60203537D1 (de) 5ht1-rezeptoragonist enthaltendes arzneimittel
NO20041485L (no) Farmasoytisk formulering omfattende (R)-bicalutamid
NO20043007L (no) Farmasoytisk suspensjon for oral administrering
FI20012242A0 (fi) Uudet farmaseuttiset yhdisteet
NO20041236L (no) Farmasoytisk formulering
DK1330280T3 (da) Lægemiddelinhalator
SE0102823D0 (sv) New drug
SE0103116D0 (sv) Pharmaceutical combination
SE0103565D0 (sv) Pharmaceutical formulation
SE0102957D0 (sv) Pharmaceutical formulation
SE0102572D0 (sv) Pharmaceutical formulation
SE0102069D0 (sv) Pharmaceutical formulation
SE0101326D0 (sv) Pharmaceutical formulation
SE0101325D0 (sv) Pharmaceutical formulation

Legal Events

Date Code Title Description
GB1A Change in the ownership or in the address of the owner
MM4A Lapsed by not paying the annual fees

Effective date: 20190424